(PRWEB) August 20, 2013 -- Sonora Quest Laboratories announced today that it has recently entered into an agreement with Oncimmune® USA LLC to offer EarlyCDT®-Lung, a simple blood test that aids physicians in the early detection of lung cancer. Sonora Quest Laboratories offers the EarlyCDT®-Lung test as a “pass-through” test, with reporting and billing being handled directly by Oncimmune®.
EarlyCDT-Lung is a ground-breaking diagnostic blood test that aids in the early detection of lung cancer. EarlyCDT-Lung has been shown to detect early and late stage cancer in research studies as well as in clinical use. Oncimmune’s EarlyCDT-Lung uses a panel of tumor antigens to diagnose autoantibodies (immuno-biomarkers) produced by the patient’s immune system when lung cancer is present. Elevation of any one of the autoantibodies in the test panel above a predetermined cut-off value suggests that a tumor might be present. Previous studies have shown that autoantibodies can be detected up to five years earlier than a tumor can be seen in routine diagnostic imaging procedures. Tests that detect autoantibodies to a single tumor protein have been available for a number of years but have had low detection rates (sensitivity).
“We are pleased to welcome Sonora Quest Laboratories as our partner to help provide EarlyCDT-Lung, a ground-breaking blood test that aids in the early detection of lung cancer.” said Greg Stanley, Chief Commercial Officer at Oncimmune USA.
Patient blood samples sent to Sonora Quest Laboratories will be analyzed at Oncimmune’s CLIA-certified laboratory located in De Soto, Kansas. More than 2,000 physicians throughout the United States are offering the test as well as numerous leading academic and medical institutions. A prospective audit of clinical data from the first 1,600 patients tested with EarlyCDT-Lung validates its utility to detect early-stage lung cancer and its overall performance, click here. Additionally, the Scottish government is conducting a 10,000-patient randomized clinical trial to validate the economic benefit of the test in screening high-risk patients, click here. The EarlyCDT® autoantibody platform is supported by 17 peer-reviewed publications, click here. EarlyCDT-Lung has a high specificity (93%), 7 times fewer false positives and 5 times better positive predictive value (PPV) than CT. Additionally, the test offers >91% accuracy, when considering a population with 2% prevalence of lung cancer (20 lung cancers per thousand).
About Sonora Quest Laboratories/Laboratory Sciences of Arizona:
Sonora Quest Laboratories, a joint venture between Banner Health and Quest Diagnostics, is the nation’s largest integrated laboratory system with approximately 2,600 employees serving more than 6 million patients annually throughout Arizona. It is the market share leader in clinical laboratory testing in Arizona, performing more than 20 million diagnostic tests per year. It offers a local comprehensive test menu which encompasses routine diagnostic testing to esoteric cytogenetic studies, including anatomic pathology and molecular biology. Ninety-eight percent of all testing is performed at the laboratory’s primary testing facilities located in Tempe, Tucson, Flagstaff, Prescott, and Yuma.
Sonora Quest Laboratories, ranked the #1 Bioscience Company in Arizona by Ranking Arizona / AZ BIG Media for two consecutive years, most recently in 2013, continues to be recognized for their exemplary quality processes. They have been named one of the Best Places to Work in Arizona by the Phoenix Business Journal for five consecutive years, most recently in 2012. In 2011, they were awarded with a Business Ethics Award by the Better Business Bureau of Greater Arizona. In 2005 they became the first and only health care establishment to ever receive the Arizona Governor’s Award for Quality. For more information about Sonora Quest Laboratories visit http://www.SonoraQuest.com.
About Oncimmune
Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune is a privately funded company located in Nottingham, UK with US headquarters and a CLIA-certified laboratory located just outside of Kansas City. The company launched a proprietary platform technology for early cancer detection, called EarlyCDT®. The first commercially available test, EarlyCDT®-Lung, a blood test to aid in the early detection of lung cancer, was released in 2009. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian.
Greg Stanley, Oncimmune, http://www.oncimmune.com, (317) 363-0071, [email protected]
SOURCE Oncimmune
Share this article